SCHEMBL1031405

SCHEMBL1031405

CCCNCCOc1ccc(NS(=O)(=O)c2ccc(CCCF)cc2)c(C)n1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ATM Q13315 2/20 0.39
POLB P06746 1/20 0.39
FFAR4 Q5NUL3 2/20 0.39
FFAR1 O14842 1/20 0.39
CYP3A4 P08684 1/20 0.38
AKT1 P31749 9/20 0.37
IRS1 P35568 1/20 0.36
GAB1 Q13480 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 1/20 0.36
METAP2 P50579 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4246749 0.99 KDM4E (0.39) KDM4EATMPOLBFFAR4FFAR1
SCHEMBL4049151 0.89 CYP3A4 (0.38) KDM4EATMPOLBFFAR4FFAR1
Hydrochloric Acid SCHEMBL4244945 0.88 CYP3A4 (0.38) KDM4EATMPOLBFFAR4FFAR1
SCHEMBL1033689 0.86 PKM (0.43) KDM4ECYP3A4LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL4251154 0.85 PKM (0.42) KDM4ECYP3A4LMNAHTTSMN1; SMN2
SCHEMBL1029637 0.83 TRPV1 (0.35) KDM4ELMNAHTTSMN1; SMN2TSHR
SCHEMBL1027372 0.83 TRPV1 (0.35) KDM4ELMNAHTTSMN1; SMN2TSHR
SCHEMBL4054899 0.83 TRPV1 (0.35) KDM4ELMNAHTTSMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL4248076 0.83 TRPV1 (0.35) KDM4ELMNAHTTSMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL4252555 0.83 TRPV1 (0.35) KDM4ELMNAHTTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed